Blog Category: On-Demand

Planning Ahead: Maintenance Therapy in Endometrial Cancer

The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy.  This led to several new trials of emerging therapies, including …

Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease

Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). …

Balancing Act: Optimizing Anticoagulation Care in Renally-Impaired Patients with NVAF or VTE

Chronic kidney disease (CKD) is a common comorbidity among patients with non-valvular atrial fibrillation (NVAF) and/or venous thromboembolism (VTE). Paradoxically, declining kidney function increases both thromboembolic and bleeding risks in patients with these conditions, requiring a fragile balance when implementing …

Anticoagulation Considerations in Renally-Impaired Patients with NVAF or VTE: Case Simulations and Commentary

Anticoagulation for renally-impaired individuals with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) often entails balancing the risk of vascular events (e.g., stroke, pulmonary embolism) with the dangers of excess bleeding. In this CME Outfitters BriefCase series, two expert clinicians …

Opioid Use Disorder: Identifying Patients At Risk and Developing Management Plans

Patients and health care professionals (HCPs) face additional challenges when the treatments prescribed for pain management (e.g., opioids) lead to substance use problems. HCPs must then re-evaluate treatment plans for acute, subacute, and chronic pain and encourage treatment for opioid …

Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD

Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is …

Racial/Ethnic Disparities in Dermatology Care: Real-World Strategies to Address Inequities in Treatment and Outcomes

Despite advances in the treatment and management of dermatologic conditions such as psoriasis, significant disparities in both treatment and outcomes persist for patients from racial/ethnic underserved groups. Patients of color are not only more likely to present with more severe …

Optimizing Care for Diverse Patient Populations with Migraine: An Exploration of Migraine Management with a Focus on CGRP Receptor Antagonists

Migraine is the most common neurological disorder, and the second most common cause of disability in the world. Despite the enormous cost it exacts on patients, the healthcare system, and the greater economy, migraine remains largely undertreated or un-treated. Racial …

Racial/Ethnic Disparities in Gastroenterology Care: Real-World Strategies to Address Inequities in Treatment and Outcomes

Despite the rising prevalence of inflammatory bowel disease (IBD) among racial and ethnic underserved populations, disparities in diagnosis, treatment, and outcomes remain. Patients of color are more likely to present with more severe disease, sometimes with extraintestinal manifestations. However, even …